<DOC>
	<DOC>NCT02208882</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability and effect on Midazolam pharmacokinetics of multiple oral doses of BMS-986120 in healthy subjects.</brief_summary>
	<brief_title>Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com 1. Healthy male and female subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations 2. Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI=Weight (kg)/[Height(m)]2 3. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and men, ages 18 to 75, inclusive 1. Concurrent, or use within 2weeks of study drug administration, of marketed or investigational, nonsteroidal antiinflammatory compounds (NSAIDS), aspirin or other antiplatelet agents, oral or parenteral anticoagulants 2. Subjects at screening or prior to first dose with the following abnormal laboratory values upon repeat testing are excluded: i) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;upper limit of normal (ULN) ii) Total bilirubin &gt;ULN, thyroidstimulating hormone (TSH) &gt;1.5 x ULN with T4 within normal limits (Subjects with mild unconjugated hyperbilirubinemia due to Gilbert's syndrome are excluded) iii) CK &gt;3 x ULN (unless exercise related and CKMB within normal limits) iv) Activated partial thromboplastin (aPTT) or Prothrombin Time (PT)/International Normalized Ratio (INR) &gt;ULN v) Blood urea nitrogen (BUN) or creatinine (Cr) &gt;ULN 3. Hemoglobin or hematocrit or platelet count &lt;lower limit of normal (LLN) 4. Bleeding time exceeding 8 minutes at predose on Day 1 5. Subjects with micro or macrohematuria and/or fecal occult blood detected during screening, baseline or documented during other recent medical assessment, unless deemed not clinically significant by the Investigator and Medical Monitor 6. Any significant acute or chronic medical illness 7. Current or recent (within 3 months of study drug administration) gastrointestinal disease 8. Any major surgery within 12 weeks of study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>